Goldman Sachs raises AbbVie stock price target to $208
Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the ...
Crain's Chicago Business17h
Already struggling booze biz dealt a new challenge: Crain's Daily Gist podcast
The U.S. surgeon general advised earlier this month that alcohol is a leading preventable cause of cancer, presenting ...
Piper Sandler raises AbbVie stock target to $227, keeps Overweight rating
Piper Sandler adjusted its financial outlook for pharmaceutical giant AbbVie (NYSE:ABBV), which currently commands a market capitalization of $301 billion, citing upcoming charges and anticipated ...
AbbVie price target raised to $227 from $220 at Piper Sandler
Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $227 from $220 and keeps an Overweight rating on ...
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price ...
STAT13h
U.S. health agencies see some chaos — but an FDA approval gets through
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
STAT16h
Veru says its drug preserved lean mass in patients taking Wegovy
An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...
Crain's Chicago Business9h
Walgreens stock tumbles on report that private equity deal is unlikely
Shares of Walgreens Boots Alliance tumbled today following a CNBC report that the Deerfield-based pharmacy chain was unlikely ...